CORONACORONA Remedies Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why buy
- • Revenue growth: 20.2% YoY
- • Profit growth: 43.6% YoY
- • ROE: 27.4%
- • RSI: 66
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
- • EMA Crossover signal (setup quality 68%)
Bull case
- • Revenue growth: 20.2% YoY
- • Profit growth: 43.6% YoY
- • ROE: 27.4%
- • RSI: 66
Bear case
- • Valuation vs sector: P/E 74.0 vs sector 40.5
- • Dividend yield: 0.42%
Key risks
- • Valuation vs sector: P/E 74.0 vs sector 40.5
- • Dividend yield: 0.42%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹71.88). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.